Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATRC NASDAQ:INO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATRCAtriCure$27.53-1.7%$29.30$26.62▼$43.18$1.40B1.28704,209 shs296,535 shsINOInovio Pharmaceuticals$1.31+6.0%$1.43$1.03▼$2.98$89.92M1.431.66 million shs6.91 million shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATRCAtriCure-4.70%+2.45%-4.04%-22.62%-6.53%INOInovio Pharmaceuticals+8.77%+10.71%+9.73%-20.51%-27.49%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATRCAtriCure$27.53-1.7%$29.30$26.62▼$43.18$1.40B1.28704,209 shs296,535 shsINOInovio Pharmaceuticals$1.31+6.0%$1.43$1.03▼$2.98$89.92M1.431.66 million shs6.91 million shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATRCAtriCure-4.70%+2.45%-4.04%-22.62%-6.53%INOInovio Pharmaceuticals+8.77%+10.71%+9.73%-20.51%-27.49%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATRCAtriCure 2.64Moderate Buy$48.7176.98% UpsideINOInovio Pharmaceuticals 2.38Hold$6.75413.70% UpsideCurrent Analyst Ratings BreakdownLatest INO and ATRC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/6/2026ATRCAtriCure Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$53.00 ➝ $55.005/4/2026ATRCAtriCure Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/20/2026ATRCAtriCure Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/1/2026ATRCAtriCure Freedom CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy3/13/2026INOInovio Pharmaceuticals OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform2/18/2026ATRCAtriCure UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$60.00 ➝ $55.002/18/2026ATRCAtriCure Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$64.00 ➝ $53.002/18/2026ATRCAtriCure OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Market Perform2/18/2026ATRCAtriCure OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$44.002/18/2026ATRCAtriCure CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform2/18/2026ATRCAtriCure Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 5/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATRCAtriCure$534.53M2.61$0.29 per share93.90$9.89 per share2.78INOInovio Pharmaceuticals$65.34K1,396.35N/AN/A$0.36 per share3.65Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATRCAtriCure-$11.45M-$0.10N/A78.64N/A-0.83%0.29%0.22%N/AINOInovio Pharmaceuticals-$84.95M-$1.68N/AN/AN/AN/A-259.70%-83.46%5/13/2026 (Estimated)Latest INO and ATRC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026INOInovio Pharmaceuticals-$0.30N/AN/AN/A$0.33 millionN/A5/5/2026Q1 2026ATRCAtriCure-$0.07$0.0022+$0.0722N/A$139.75 million$141.25 million3/12/2026Q4 2025INOInovio Pharmaceuticals-$0.37$0.31+$0.68$0.31$0.33 millionN/A2/17/2026Q4 2025ATRCAtriCure-$0.04$0.06+$0.10$0.04$140.50 million$140.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthATRCAtriCureN/AN/AN/AN/AN/AINOInovio PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATRCAtriCure0.133.962.99INOInovio PharmaceuticalsN/A1.401.40Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATRCAtriCure99.11%INOInovio Pharmaceuticals26.79%Insider OwnershipCompanyInsider OwnershipATRCAtriCure4.00%INOInovio Pharmaceuticals1.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATRCAtriCure1,30050.64 million48.61 millionOptionableINOInovio Pharmaceuticals32069.44 million68.26 millionOptionableINO and ATRC HeadlinesRecent News About These CompaniesInovio Pharmaceuticals (INO) to Release Quarterly Earnings on TuesdayMay 5 at 11:46 AM | marketbeat.comInovio Pharmaceuticals, Inc. (NASDAQ:INO) Given Average Rating of "Hold" by BrokeragesMay 5 at 4:28 AM | marketbeat.comINOVIO to Report First Quarter Financial Results on May 13, 2026May 1, 2026 | finance.yahoo.comINOVIO to Report First Quarter Financial Results on May 13, 2026May 1, 2026 | prnewswire.comPacira Q1 Earnings Miss Estimates on Higher Costs, Revenues Rise Y/YMay 1, 2026 | finance.yahoo.comQ32 Bio Gears Up to Report Q1 Earnings: What's in the Cards?April 30, 2026 | finance.yahoo.comInovio Pharmaceuticals, Inc. (NASDAQ:INO) Sees Significant Growth in Short InterestApril 29, 2026 | marketbeat.comInovio Pharmaceuticals Inc. stock outperforms competitors on strong trading dayApril 27, 2026 | marketwatch.comINBX Stock Up on Upbeat Clinical Update From Colorectal Cancer StudyApril 23, 2026 | finance.yahoo.comViking Therapeutics Gears Up for Q1 Earnings: Here's What to ExpectApril 21, 2026 | finance.yahoo.comNKTX Stock Up on Upbeat Regulatory Update on Lead Autoimmune ProgramApril 17, 2026 | finance.yahoo.comTVTX Stock Soars on FDA Nod for Filspari in Second Kidney IndicationApril 15, 2026 | finance.yahoo.comInovio Pharmaceuticals, Inc. (NASDAQ:INO) Given Average Recommendation of "Hold" by AnalystsApril 10, 2026 | marketbeat.comInovio Pharmaceuticals (INO) price target decreased by 12.21% to 6.90April 10, 2026 | msn.comWhat's going on with Inovio Pharmaceuticals stock on Tuesday?April 7, 2026 | msn.comInovio Deadline Today: Rosen Law Firm Urges Inovio Pharmaceuticals, Inc. (NASDAQ: INO) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About ...April 7, 2026 | tmcnet.comPomerantz Law Firm Announces the Filing of a Class Action Against Inovio Pharmaceuticals, Inc. and Certain Officers – INOApril 7, 2026 | globenewswire.comINO Deadline Today: INO Investors with Losses in Excess of $100K Have Opportunity to Lead Inovio Pharmaceuticals, Inc. Securities Fraud LawsuitApril 7, 2026 | prnewswire.comInovio Deadline Today: Rosen Law Firm Urges Inovio Pharmaceuticals, Inc. (NASDAQ: INO) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their RightsApril 7, 2026 | businesswire.comINO CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Inovio Pharmaceuticals Investors of Securities Class Action Deadline on April 7, 2026April 7, 2026 | businesswire.comINO Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Inovio Pharmaceuticals, Inc. Securities Lawsuit -- The Gross Law FirmApril 7, 2026 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeINO and ATRC Company DescriptionsAtriCure NASDAQ:ATRC$27.52 -0.49 (-1.73%) As of 01:24 PM Eastern This is a fair market value price provided by Massive. Learn more.AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.Inovio Pharmaceuticals NASDAQ:INO$1.31 +0.07 (+5.97%) As of 01:23 PM Eastern This is a fair market value price provided by Massive. Learn more.Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Nuts and Bolts AI Play Gains Momentum: Astera Labs Targets Raised Anheuser-Busch Stock Jumps as Volume Growth Signals Turnaround Light Speed Returns: Corning Cashes In on NVIDIA Growth Boarding Passes Now Being Issued for the Ultimate eVTOL Arbitrage DigitalOcean’s AI Surge: How Far Can This Rally Go? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
